New combo therapy aims to boost cancer clearance before surgery

NCT ID NCT07277439

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 16 times

Summary

This study tests whether adding an immune-boosting drug (thymosin alpha 1) to standard chemo-immunotherapy and radiation can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 participants will receive either the standard treatment or the standard plus thymosin before surgery. The main goal is to see if the combination leads to a higher rate of complete cancer disappearance (pathological complete response) at the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

First Affiliated Hospital of Nanjing Medical Unviersity
RECRUITING

Nanjing, Jiangsu, 210000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GASTRIC CANCER